Korean patients closer to affordable access for groundbreaking cancer treatment, Enhertu

CAR-T Digest - August 2020

19 Mar 2024: Korean patients closer to affordable access for groundbreaking cancer treatment, Enhertu

Negotiations concluded for reimbursement of Enhertu, a novel cancer drug, by the National Health Insurance Service (NHIS) in Korea
Pending approval, Enhertu could be available with insurance benefits for Korean cancer patients in April 2024
The drug, approved domestically in September 2022, demonstrates significant improvements in survival rates for HER2-positive breast and gastric cancers
Enhertu marks a new standard of care for HER2 low-expressing breast cancer, showing promising results in clinical studies
Despite initial challenges, including high treatment costs and delays in reimbursement review, Enhertu’s flexible ICER threshold application marks a significant breakthrough
The drug’s potential expansion for HER2 low-expressing breast cancer is under MFDS review, offering hope for broader accessibility in the future